Commerzbank Aktiengesellschaft FI Sells 106,902 Shares of Johnson & Johnson (NYSE:JNJ)

Commerzbank Aktiengesellschaft FI decreased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 9.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 969,151 shares of the company's stock after selling 106,902 shares during the period. Johnson & Johnson makes up 3.7% of Commerzbank Aktiengesellschaft FI's portfolio, making the stock its 6th largest position. Commerzbank Aktiengesellschaft FI's holdings in Johnson & Johnson were worth $160,724,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank bought a new stake in Johnson & Johnson in the 4th quarter valued at $4,390,037,000. GAMMA Investing LLC lifted its position in Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock valued at $1,196,596,000 after acquiring an additional 7,185,977 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock valued at $3,844,580,000 after acquiring an additional 4,842,582 shares in the last quarter. Janus Henderson Group PLC lifted its position in Johnson & Johnson by 134.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock valued at $1,149,536,000 after acquiring an additional 4,559,147 shares in the last quarter. Finally, Northern Trust Corp lifted its position in Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company's stock valued at $4,456,201,000 after acquiring an additional 3,363,235 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Raymond James Financial cut their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Royal Bank Of Canada boosted their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Finally, Wall Street Zen raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Eleven analysts have rated the stock with a hold rating, nine have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $174.11.

Johnson & Johnson Stock Performance

JNJ traded up $0.67 on Friday, reaching $163.65. The company had a trading volume of 9,764,459 shares, compared to its average volume of 8,138,164. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The stock has a market cap of $393.75 billion, a P/E ratio of 17.50, a P/E/G ratio of 2.18 and a beta of 0.41. The company's fifty day moving average is $154.10 and its 200 day moving average is $154.84. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the prior year, the business earned $2.82 EPS. Johnson & Johnson's quarterly revenue was up 5.8% on a year-over-year basis. As a group, analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.18%. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.